LEXARIA BIOSCIENCE CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.99 USD | +2.40% |
|
-2.92% | +139.20% |
| May. 21 | Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise | MT |
| May. 17 | Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study | CI |
Presenter SpeechSpencer Israel (Analysts)All right. A little while ago, somebody in chat was p...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Companyâs patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.92
USD
Average target price
10
USD
Spread / Average Target
+242.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +139.20% | 37.63M | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Transcript : Lexaria Bioscience Corp. Presents at Benzinga Virtual Global Small Cap Conference, May-13-2021 03
